Cytokines and systemic lupus erythematosus.
作者信息
Dean G S, Tyrrell-Price J, Crawley E, Isenberg D A
机构信息
Centre for Rheumatology/ Bloomsbury Rheumatology Unit, Department of Medicine, University College, London, UK.
出版信息
Ann Rheum Dis. 2000 Apr;59(4):243-51. doi: 10.1136/ard.59.4.243.
Abstract
摘要
相似文献
1
Cytokines and systemic lupus erythematosus.
Ann Rheum Dis. 2000 Apr;59(4):243-51. doi: 10.1136/ard.59.4.243.
2
Research Progress on Regulatory B Cells in Systemic Lupus Erythematosus.
Biomed Res Int. 2019 May 22;2019:7948687. doi: 10.1155/2019/7948687. eCollection 2019.
3
Cytokines in systemic lupus erythematosus, London, UK.
Arthritis Res Ther. 2003;5(4):160-4. doi: 10.1186/ar767. Epub 2003 Apr 30.
4
New pieces to the SLE cytokine puzzle.
Clin Immunol. 1999 Apr;91(1):1-5. doi: 10.1006/clim.1999.4704.
5
A Proinflammatory Cytokine Network Profile in Th1/Type 1 Effector B Cells Delineates a Common Group of Patients in Four Systemic Autoimmune Diseases.
Arthritis Rheumatol. 2021 Aug;73(8):1550-1561. doi: 10.1002/art.41697. Epub 2021 Jul 9.
6
Recent advances in cytokines in cutaneous and systemic lupus erythematosus.
J Dermatol. 2011 Sep;38(9):839-49. doi: 10.1111/j.1346-8138.2011.01237.x. Epub 2011 Jul 18.
7
Tumour necrosis factor and other proinflammatory cytokines in systemic lupus erythematosus: a rationale for therapeutic intervention.
Lupus. 2004;13(5):344-7. doi: 10.1191/0961203303lu1024oa.
8
Regulatory T-cell-associated cytokines in systemic lupus erythematosus.
J Biomed Biotechnol. 2011;2011:463412. doi: 10.1155/2011/463412. Epub 2011 Dec 18.
9
Tumor necrosis factor and interferon gamma: relevance for immune regulation and genetic predisposition to autoimmune disease.
Semin Immunol. 1992 Jun;4(3):147-54.
10
The interplay of dendritic cell subsets in systemic lupus erythematosus.
Immunol Cell Biol. 2002 Oct;80(5):484-8. doi: 10.1046/j.1440-1711.2002.01112.x.
引用本文的文献
1
Systemic lupus erythematosus: pathogenesis and targeted therapy.
Mol Biomed. 2024 Oct 30;5(1):54. doi: 10.1186/s43556-024-00217-8.
2
Brain-immune interactions: implication for cognitive impairments in Alzheimer's disease and autoimmune disorders.
J Leukoc Biol. 2024 Nov 27;116(6):1269-1290. doi: 10.1093/jleuko/qiae134.
3
Fas gene dosage tunes the extent of lymphoproliferation and T cell differentiation in lupus.
Clin Immunol. 2024 Jan;258:109874. doi: 10.1016/j.clim.2023.109874. Epub 2023 Dec 17.
4
Cardiovascular changes in the NZB/W F1 mouse model of lupus nephritis.
Front Cardiovasc Med. 2023 Jul 24;10:1182193. doi: 10.3389/fcvm.2023.1182193. eCollection 2023.
5
CTLA4 Gene Polymorphism and its Association with Disease Occurrence, Clinical Manifestations, Serum Markers and Cytokine Levels in SLE Patients from North India.
Indian J Dermatol. 2022 May-Jun;67(3):311. doi: 10.4103/ijd.ijd_82_22.
6
Dynamically modeling the effective range of IL-2 dosage in the treatment of systemic lupus erythematosus.
iScience. 2022 Aug 11;25(9):104911. doi: 10.1016/j.isci.2022.104911. eCollection 2022 Sep 16.
7
Applying Modeling and Simulations for Rational Dose Selection of Novel Toll-Like Receptor 7/8 Inhibitor Enpatoran for Indications of High Medical Need.
Clin Pharmacol Ther. 2022 Aug;112(2):297-306. doi: 10.1002/cpt.2606. Epub 2022 May 21.
8
A Small Step, a Giant Leap: Somatic Hypermutation of a Single Amino Acid Leads to Anti-La Autoreactivity.
Int J Mol Sci. 2021 Nov 7;22(21):12046. doi: 10.3390/ijms222112046.
9
Preclinical Dose-Escalation Study of ZSJ-0228, a Polymeric Dexamethasone Prodrug, in the Treatment of Murine Lupus Nephritis.
Mol Pharm. 2021 Nov 1;18(11):4188-4197. doi: 10.1021/acs.molpharmaceut.1c00567. Epub 2021 Sep 27.
10
Phase 1 double-blind randomized safety trial of the Janus kinase inhibitor tofacitinib in systemic lupus erythematosus.
Nat Commun. 2021 Jun 7;12(1):3391. doi: 10.1038/s41467-021-23361-z.
本文引用的文献
1
Single nucleotide polymorphic haplotypes of the interleukin-10 5' flanking region are not associated with renal disease or serology in Caucasian patients with systemic lupus erythematosus.
Arthritis Rheum. 1999 Sep;42(9):2017-8. doi: 10.1002/1529-0131(199909)42:9<2017::AID-ANR34>3.0.CO;2-I.
2
The relationship between defects in lymphocyte production of transforming growth factor-beta1 in systemic lupus erythematosus and disease activity or severity.
Lupus. 1999;8(2):90-4. doi: 10.1191/096120399678847489.
3
Serum IL-6, TNFalpha, p55 srTNFalpha, p75srTNFalpha, srIL-2alpha levels and disease activity in systemic lupus erythematosus.
Clin Rheumatol. 1999;18(1):17-22. doi: 10.1007/s100670050045.
4
Circulating interleukin-16 in systemic lupus erythematosus.
Br J Rheumatol. 1998 Dec;37(12):1334-7. doi: 10.1093/rheumatology/37.12.1334.
5
Th1 (IL-2, interferon-gamma (IFN-gamma)) and Th2 (IL-10, IL-4) cytokine production by peripheral blood mononuclear cells (PBMC) from patients with systemic lupus erythematosus (SLE).
Clin Exp Immunol. 1999 Jan;115(1):189-95. doi: 10.1046/j.1365-2249.1999.00766.x.
6
Infectious tolerance.
Curr Opin Immunol. 1998 Oct;10(5):518-24. doi: 10.1016/s0952-7915(98)80217-3.
7
[Soluble cytokinin receptors in renal vasculitis and lupus nephritis].
Cas Lek Cesk. 1998 May 4;137(9):271-5.
8
Prolactin and interleukin-6 in neuropsychiatric lupus erythematosus.
Clin Rheumatol. 1998;17(2):110-4. doi: 10.1007/BF01452255.
9
Elevated interleukin-10 levels correlated with disease activity in systemic lupus erythematosus.
Clin Exp Rheumatol. 1998 May-Jun;16(3):283-8.
10
Interleukin-10 promoter polymorphisms in Southern Chinese patients with systemic lupus erythematosus.
Arthritis Rheum. 1998 Jun;41(6):1090-5. doi: 10.1002/1529-0131(199806)41:6<1090::AID-ART16>3.0.CO;2-6.
Zotero 插件